339 related articles for article (PubMed ID: 21854363)
1. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
3. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
[TBL] [Abstract][Full Text] [Related]
6. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
7. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
8. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
[TBL] [Abstract][Full Text] [Related]
9. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
11. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
12. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
15. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.
Beuers U; Bilzer M; Chittattu A; Kullak-Ublick GA; Keppler D; Paumgartner G; Dombrowski F
Hepatology; 2001 May; 33(5):1206-16. PubMed ID: 11343250
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
17. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
Paumgartner G; Beuers U
Clin Liver Dis; 2004 Feb; 8(1):67-81, vi. PubMed ID: 15062194
[TBL] [Abstract][Full Text] [Related]
19. [Ursodeoxycholic acid: history and clinical implications].
Beuers U; Trampert DC
Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
[TBL] [Abstract][Full Text] [Related]
20. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.
Lim SC; Duong HQ; Choi JE; Lee TB; Kang JH; Oh SH; Han SI
Carcinogenesis; 2011 May; 32(5):723-31. PubMed ID: 21362627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]